DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD)

Clinical trials for DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD) explained in plain language.

Never miss a new study

Get alerted when new DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD) trials appear

Sign up with your email to follow new studies for DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for Alzheimer's in down syndrome: drug trial launches

Disease control Not yet recruiting

This study tests a drug called mivelsiran in 58 adults with Down syndrome who have early-stage Alzheimer's. Participants receive either the drug or a placebo via injection into the spine every few months for two years. The goal is to see if the drug can reduce brain changes linke…

Matched conditions: DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD)

Phase: PHASE2 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control

Last updated Jun 27, 2026 13:05 UTC

DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD)

Get alerted when new DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD) trials appear

New hope for Alzheimer's in down syndrome: drug trial launches